志賀氏菌抗藥性的研究-免費(fèi)閱讀
【正文】 因此 ，這些 藥物應(yīng)該 不再被認(rèn)為是適當(dāng)?shù)闹委熃?jīng)驗(yàn) 。在中國(guó)，關(guān)于細(xì)菌性痢疾的事件每年會(huì)發(fā)生一千七百萬(wàn)例，以及兩十萬(wàn)感染痢疾的病人在醫(yī)院被確診，使志賀氏菌病成為世界四大須申報(bào)的傳染病之一。 石磊 倪庚壬 彭超 柳彬彬 標(biāo)題 Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2022–2022 2022年 — 2022年在中國(guó)上海對(duì)志賀氏菌抗藥性的研究 Abstract A retrospective study conducted on patients with diarrhea in Shanghai, China from 2022–2022, indicated thatof 77,600 samples collected, 1,635 (%) tested positive for Shigella. Species isolated included S. sonnei (1,066,%), S. exneri (569, %), and S. boydii (3, %). Most of the Shigella isolates were found to be resistant tostreptomycin (%), trimethoprim (%), ampicillin (%), and nalidixic acid (%). Additionally,many isolates were resistant to tetracycline (%),trimethoprim
環(huán)評(píng)公示相關(guān)推薦
鄂ICP備17016276號(hào)-1